Bulletin
Investor Alert

Cyclo Therapeutics Inc.

NAS: CYTH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Cyclo Therapeutics Inc.

After Hours

 --Quotes are delayed by 20 min

Jan 21, 2022, 6:57 p.m.

CYTH
/zigman2/quotes/207006339/composite

$

3.76

Change

-0.06 -1.57%

Volume

Volume 100

Quotes are delayed by 20 min

/zigman2/quotes/207006339/composite

Previous close

$ 3.84

$ 3.82

Change

-0.02 -0.52%

Day low

Day high

$3.76

$3.98

Open

52 week low

52 week high

$3.43

$17.75

Open

Company Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-bas...

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

Valuation

Price to Sales Ratio

7.70

Price to Book Ratio

1.99

Enterprise Value to EBITDA

-2.38

Enterprise Value to Sales

18.59

Total Debt to Enterprise Value

-0.03

Efficiency

Revenue/Employee

112,922.00

Income Per Employee

-1,117,700.00

Receivables Turnover

6.14

Total Asset Turnover

0.10

Liquidity

Current Ratio

3.83

Quick Ratio

3.76

Cash Ratio

3.50

Profitability

Gross Margin

-192.33

Operating Margin

-991.99

Pretax Margin

-989.80

Net Margin

-989.80

Return on Assets

-97.72

Return on Equity

-157.03

Return on Total Capital

-154.04

Return on Invested Capital

-155.68

Capital Structure

Total Debt to Total Equity

1.86

Total Debt to Total Capital

1.83

Total Debt to Total Assets

1.37

Long-Term Debt to Equity

0.60

Long-Term Debt to Total Capital

0.59

Officers and Executives

Name Age Officer Since Title
Mr. Nathan Scott Fine 64 2014 Executive Chairman & Chief Executive Officer
Dr. Jeffrey L. Tate 61 2010 Director, Chief Operating & Quality Officer
Mr. Joshua M. Fine 38 2014 Chief Financial Officer & Secretary
Dr. Lise Lund Kjems - 2021 Chief Medical Officer
Dr. Sharon Hrynkow 58 2015 Chief Scientific Officer & SVP-Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
11/25/2020 Joshua M. Fine
Chief Financial Officer 		15,000   Acquisition at $0.08 per share. 1,200
11/23/2020 Joshua M. Fine
Chief Financial Officer 		10,000   Acquisition at $0.08 per share. 800
09/30/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/30/2020 Armistice Capital LLC
5,500   Disposition at $0.13 per share. 715
09/29/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/29/2020 Armistice Capital LLC
5,000   Disposition at $0.14 per share. 700
09/28/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/28/2020 Armistice Capital LLC
4,966   Disposition at $0.13 per share. 645
09/24/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/24/2020 Armistice Capital LLC
38,257   Disposition at $0.13 per share. 4,973
09/23/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/23/2020 Armistice Capital LLC
50,000   Disposition at $0.14 per share. 7,000
09/22/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/22/2020 Armistice Capital LLC
17,000   Disposition at $0.15 per share. 2,550
09/21/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/21/2020 Armistice Capital LLC
100,000   Disposition at $0.15 per share. 15,000
09/16/2020 Armistice Capital LLC
0   Disposition at $0 per share. 0
09/16/2020 Armistice Capital LLC
125,000   Disposition at $0.16 per share. 20,000
/news/latest/company/us/cyth

MarketWatch News on CYTH

  1. Cyclo Therapeutics stock price target cut to $16 from $25 at Maxim Group

    6:45 a.m. Oct. 8, 2021

    - Tomi Kilgore

  2. Cyclo Therapeutics stock price target raised to $25 from $12 at Maxim Group

    12:39 p.m. Feb. 9, 2021

    - Tomi Kilgore

  3. Cyclo Therapeutics started at buy with $12 stock price target at Maxim Group

    7:57 a.m. Dec. 17, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/cyth

Other News on CYTH

  1. Anti-Amyloid Drugs: The Failure Of Success

    7:04 a.m. Jan. 1, 2022

    - Seeking Alpha

  2. RDHL, ARDX and BRFS among pre market gainers

    8:58 a.m. Dec. 6, 2021

    - Seeking Alpha

  4. SAVA, CEI and EYES among mid-day movers

    12:39 p.m. Nov. 17, 2021

    - Seeking Alpha

  5. Rivian Automotive, DLocal, StoneCo among premarket losers' pack

    8:36 a.m. Nov. 17, 2021

    - Seeking Alpha

  6. Cyclo Therapeutics secures $12M capital through equity raise

    1:52 a.m. Nov. 17, 2021

    - Seeking Alpha

  7. XM, CFMS and PROG among pre market gainers

    8:37 a.m. Nov. 16, 2021

    - Seeking Alpha

  11. Cyclo Therapeutics names Lise Kjems as chief medical officer

    7:12 a.m. Sept. 27, 2021

    - Seeking Alpha

  13. The Post-Biogen, Post-Amyloid World For Alzheimer's Disease

    10:34 a.m. June 20, 2021

    - Seeking Alpha

  15. Cyclo therapeutics to join Russell 2000 Index

    8:12 a.m. June 14, 2021

    - Seeking Alpha

  16. Annovis Bio triggers Alzheimer's med-driven rally

    12:52 p.m. May 21, 2021

    - Seeking Alpha

  17. YALA, OBLN, ONTX and CRDF among midday movers

    11:42 a.m. May 21, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Cyclo Therapeutics, Inc.

6714 NW 16th Street

Suite B

Gainesville, Florida 32653

Phone

1 3864188060

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

View SEC Filings

Revenue

$903,376

Net Income

$-8.94M

Employees

8.00

Annual Report for CYTH

/news/pressrelease/company/us/cyth

Press Releases on CYTH

  5. Cyclo Falls After IPO

    10:12 a.m. Nov. 17, 2021

    - Baystreet.ca

  7. Cyclo Therapeutics Announces Proposed Public Offering of Common Stock

    4:27 p.m. Nov. 16, 2021

    - BusinessWire - BZX

  9. Cyclo Therapeutics to Present at the Virtual Investor Roundtable Event

    8:05 a.m. Nov. 10, 2021

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.